{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:09:30Z","timestamp":1778490570298,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]},{"name":"European Union Funds","award":["J05-LVPA-K-01-0032"],"award-info":[{"award-number":["J05-LVPA-K-01-0032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06396-z","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:13:25Z","timestamp":1776046405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of prostate cancer diagnostic models based on PCA3 and TMPRSS2:ERG RNA biomarkers from post-DRE and non-DRE urine specimens"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-8989","authenticated-orcid":false,"given":"Mantvydas","family":"Lopeta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3638-4216","authenticated-orcid":false,"given":"Sigitas","family":"Paliksa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Belevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Ukanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kasiliauskiene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dziuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrida","family":"Zutautaite-Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0745-5708","authenticated-orcid":false,"given":"Marija","family":"Barisiene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnas","family":"Bakavicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramunas","family":"Mickevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvydas","family":"Zykus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albertas","family":"Ulys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linas","family":"Juodele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feliksas","family":"Jankevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Jievaltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-1645","authenticated-orcid":false,"given":"Julius","family":"Gagilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"6396_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C et al (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69:428\u201335. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.046","journal-title":"Eur Urol"},{"key":"6396_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081963","volume":"13","author":"D Milonas","year":"2021","unstructured":"Milonas D, Ruzgas T, Venclovas Z, Jievaltas M, Joniau S (2021) Impact of grade groups on prostate cancer-specific and other-cause mortality: competing risk analysis from a large single institution series. Cancers (Basel) 13:1963. https:\/\/doi.org\/10.3390\/cancers13081963","journal-title":"Cancers (Basel)"},{"key":"6396_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"key":"6396_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12325-016-0450-2","volume":"34","author":"A B\u00f6ker","year":"2017","unstructured":"B\u00f6ker A, Kuczyk MA, Kramer MW, Merseburger AS, Kr\u00fcger K, Imkamp F et al (2017) True incidence of Gleason 6 pathology in patients with metastatic castration resistant prostate cancer (mCRPC). Adv Ther 34:171\u20139. https:\/\/doi.org\/10.1007\/s12325-016-0450-2","journal-title":"Adv Ther"},{"key":"6396_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pros.20759","volume":"68","author":"C Gosselaar","year":"2008","unstructured":"Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schr\u00f6der FH (2008) The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68:985\u2013993. https:\/\/doi.org\/10.1002\/pros.20759","journal-title":"Prostate"},{"key":"6396_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1370\/afm.2205","volume":"16","author":"L Naji","year":"2018","unstructured":"Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O et al (2018) Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med 16:149\u201354. https:\/\/doi.org\/10.1370\/afm.2205","journal-title":"Ann Fam Med"},{"key":"6396_CR7","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gr\u00f6nberg","year":"2015","unstructured":"Gr\u00f6nberg H, Adolfsson J, Aly M, Nordstr\u00f6m T, Wiklund P, Brandberg Y et al (2015) Prostate cancer screening in men aged 50\u201369 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol 16:1667\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(15)00361-7","journal-title":"Lancet Oncol"},{"key":"6396_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","volume":"6","author":"D Eldred-Evans","year":"2023","unstructured":"Eldred-Evans D, Tam H, Sokhi H, Padhani AR, Connor M, Price D et al (2023) An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM study. Eur Urol Oncol 6:295\u2013302. https:\/\/doi.org\/10.1016\/j.euo.2023.03.009","journal-title":"Eur Urol Oncol"},{"key":"6396_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B, Hendriks R, Padhani AR, Hoogenboom M et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75:570\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.023","journal-title":"Eur Urol"},{"key":"6396_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/ijms20071637","volume":"20","author":"DF Osses","year":"2019","unstructured":"Osses DF, Roobol MJ, Schoots IG (2019) Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int J Mol Sci 20:1637. https:\/\/doi.org\/10.3390\/ijms20071637","journal-title":"Int J Mol Sci"},{"key":"6396_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.eururo.2018.08.019","volume":"74","author":"J McKiernan","year":"2018","unstructured":"McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G et al (2018) A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2\u201310 ng\/ml at initial biopsy. Eur Urol 74:731\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.019","journal-title":"Eur Urol"},{"key":"6396_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JU.0000000000001430","volume":"205","author":"JJ Tosoian","year":"2021","unstructured":"Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE et al (2021) Use of the MyProstateScore test to rule out clinically significant cancer: validation of a straightforward clinical testing approach. J Urol 205:732\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000001430","journal-title":"J Urol"},{"key":"6396_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.juro.2013.02.018","volume":"190","author":"MC Gittelman","year":"2013","unstructured":"Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ et al (2013) PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 190:64\u20139. https:\/\/doi.org\/10.1016\/j.juro.2013.02.018","journal-title":"J Urol"},{"key":"6396_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Van Neste","year":"2016","unstructured":"Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA et al (2016) Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 70:740\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.012","journal-title":"Eur Urol"},{"key":"6396_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2007.11.003","volume":"389","author":"LJ Sokoll","year":"2008","unstructured":"Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL et al (2008) A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389:1\u20136. https:\/\/doi.org\/10.1016\/j.cca.2007.11.003","journal-title":"Clin Chim Acta"},{"key":"6396_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP et al (2016) Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 70:45\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.039","journal-title":"Eur Urol"},{"key":"6396_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02779-w","volume":"21","author":"B Van Calster","year":"2023","unstructured":"Van Calster B, Steyerberg EW, Wynants L, van Smeden M (2023) There is no such thing as a validated prediction model. BMC Med 21:70. https:\/\/doi.org\/10.1186\/s12916-023-02779-w","journal-title":"BMC Med"},{"key":"6396_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","volume":"25","author":"E Margolis","year":"2022","unstructured":"Margolis E, Brown G, Partin A, Carter B, McKiernan J, Tutrone R et al (2022) Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) prostate intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis 25:296\u2013301. https:\/\/doi.org\/10.1038\/s41391-021-00456-8","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6396_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08608-z","volume":"12","author":"A Kretschmer","year":"2022","unstructured":"Kretschmer A, Kajau H, Margolis E, Tutrone R, Grimm T, Trottmann M et al (2022) Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy. Sci Rep 12:4777. https:\/\/doi.org\/10.1038\/s41598-022-08608-z","journal-title":"Sci Rep"},{"key":"6396_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","volume":"52","author":"J Groskopf","year":"2006","unstructured":"Groskopf J, Aubin SMJ, Deras IL, Blase A, Bodrug S, Clark C et al (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52:1089\u201395. https:\/\/doi.org\/10.1373\/clinchem.2005.063289","journal-title":"Clin Chem"},{"key":"6396_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030789","volume":"15","author":"M Yazbek Hanna","year":"2023","unstructured":"Yazbek Hanna M, Winterbone M, O\u2019Connell SP, Olivan M, Hurst R, Mills R et al (2023) Gene-transcript expression in urine supernatant and urine cell-sediment are different but equally useful for detecting prostate cancer. Cancers (Basel) 15:789. https:\/\/doi.org\/10.3390\/cancers15030789","journal-title":"Cancers (Basel)"},{"key":"6396_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.juro.2013.11.001","volume":"191","author":"S Dijkstra","year":"2014","unstructured":"Dijkstra S, Birker IL, Smit FP, Leyten GHJM, de Reijke TM, van Oort IM et al (2014) Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 191:1132\u20138. https:\/\/doi.org\/10.1016\/j.juro.2013.11.001","journal-title":"J Urol"},{"key":"6396_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0869-y","volume":"17","author":"C Shao","year":"2018","unstructured":"Shao C, Yang F, Miao S, Liu W, Wang C, Shu Y et al (2018) Role of hypoxia-induced exosomes in tumor biology. Mol Cancer 17:120. https:\/\/doi.org\/10.1186\/s12943-018-0869-y","journal-title":"Mol Cancer"},{"key":"6396_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1615\/CritRevOncog.v20.i5-6.130","volume":"20","author":"G Deep","year":"2015","unstructured":"Deep G, Panigrahi GK (2015) Hypoxia-induced signaling promotes prostate cancer progression: exosomes role as messenger of hypoxic response in tumor microenvironment. Crit Rev Oncog 20:419\u2013434. https:\/\/doi.org\/10.1615\/CritRevOncog.v20.i5-6.130","journal-title":"Crit Rev Oncog"},{"key":"6396_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/JU.0000000000004421","volume":"213","author":"JJ Tosoian","year":"2025","unstructured":"Tosoian JJ, Zhang Y, Meyers JI, Heaton S, Siddiqui J, Xiao L et al (2025) Clinical validation of MyProstateScore 2.0 testing using first-catch, non-digital rectal examination urine. J Urol 213:581\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000004421","journal-title":"J Urol"},{"key":"6396_CR26","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1007\/s00261-024-04727-5","volume":"50","author":"J Kemesiene","year":"2025","unstructured":"Kemesiene J, Nicolau C, Cholstauskas G, Zviniene K, Lopeta M, Veneviciute S et al (2025) Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-na\u00efve patients. Abdom Radiol (NY) 50:3816\u201326. https:\/\/doi.org\/10.1007\/s00261-024-04727-5","journal-title":"Abdom Radiol (NY)"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06396-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:17:33Z","timestamp":1778487453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06396-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6396"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06396-z","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Lopeta, S. Paliksa, and J. Belevicius are employees of JSC Diagnolita. M. Ukanis, L. Kasiliauskiene, L. Dziuge, I. Zutautaite-Varela, and J. Gagilas are former employees of JSC Diagnolita. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. Biomedical research protocol No. 2015-PVD was approved by the Lithuanian Bioethics Committee, approval No. L-15-06\/1.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"303"}}